NCT02515630

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Sierra Oncology LLC - a GSK company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the transfusion independence response rate in transfusion-dependent adults with myelofibrosis after treatment with momelotinib (MMB).

Conditions

• Primary Myelofibrosis (PMF)
• Post-polycythemia Vera (Post-PV) Myelofibrosis
• Postessential Thrombocythemia (Post-ET) Myelofibrosis

Interventions

Type	Name	Description
DRUG	MMB	Momelotinib (MMB) tablet administered orally once daily

Timeline

• Start date: 2016-01-29
• Primary completion: 2017-07-18
• Completion: 2017-08-15
• First posted: 2015-08-05
• Last updated: 2023-06-18
• Results posted: 2021-01-20

Locations

13 sites across 2 countries: United States, Canada